Trial Profile
A randomized, open-label, dose-blinded, multicenter, 6-month study of safety and tolerability of 3 dose levels of SM-13496 [lurasidone] in patients with schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sumitomo Pharmaceuticals America
- 19 Apr 2011 Status changed from active, no longer recruiting to completed.
- 09 Oct 2005 New trial record.